Annovis Bio, Inc. Common Stock (ANVS)

Competitors to Annovis Bio, Inc. Common Stock (ANVS)

Axovant Gene Therapies Ltd.

Axovant Gene Therapies is another player in the neurodegenerative space, focusing mainly on gene therapies for conditions like Alzheimer's and other cognitive disorders. Their advanced gene therapy approach distinguishes them from Annovis Bio's small molecules, and they seek to employ cutting-edge genomic innovations. Axovant holds a competitive advantage in the technology associated with gene therapy, promising more targeted and potentially long-lasting effects on neurodegenerative diseases than conventional pharmacological approaches that Annovis is exploring.

Cortexyme, Inc.

Cortexyme, Inc. focuses on developing therapeutics for neurodegenerative diseases, particularly targeting the Alzheimer's disease market, similar to Annovis Bio's mission. Both companies are engaged in innovative clinical trials for their respective compounds and are competing for the same patient population. Cortexyme's primary competitive advantage lies in its unique approach to targeting specific bacterial infections implicated in Alzheimer's disease, which distinguishes it in a crowded field of neurodegenerative treatments. Annovis Bio’s distinct mechanism on neurodegeneration gives it another angle, making them both key competitors in this therapeutic niche.

Prothena Corporation plc 

Prothena Corporation is actively developing therapies for neurodegenerative diseases, with robust pipeline candidates targeting proteins involved in conditions such as Alzheimer's. Both companies aim to improve cognitive function and quality of life for patients, leading to direct competition for investment, partnerships, and market share. Prothena has a competitive edge due to its established pipeline and collaborative relationships with large pharmaceutical companies, giving it resources and reach that Annovis may still be working to build.